OpGen, Inc.

149 articles with OpGen, Inc.

• OpGen Reports First Quarter 2022 Financial Results and Provides Business Update

  5/12/2022

  OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its first quarter 2022 financial and operating results.

• OpGen to Provide Business Update and Financial Results for the First Quarter 2022 on May 12th at 4:30 p.m. Eastern Time

  4/28/2022

  OpGen, Inc. announced that the Company will provide a business update and report its first quarter 2022 financial results after the close of the U.S. financial markets on Thursday, May 12th, 2022.

• OpGen’s Subsidiary Curetis and European Investment Bank Plan to Restructure Debt Repayment

  4/25/2022

  OpGen, Inc. announced that its subsidiary, Curetis GmbH, and the European Investment Bank expect to restructure the repayment of the first tranche which matured on April 22, 2022.

• OpGen’s Subsidiary Ares Genetics Commercially Launches New Sequencing and Analysis Services Globally

  4/20/2022

  OpGen, Inc. announced that its subsidiary, Ares Genetics, which strives to become a leader in bacterial genomics and AI-powered prediction of antimicrobial resistance, is commercially launching a series of new genome sequencing and analysis services globally.

• OpGen’s subsidiary Ares Genetics provides update on collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)

  4/6/2022

  OpGen, Inc. announced that its subsidiary, Ares Genetics, which strives to become a leader in bacterial genomics and AI-powered prediction of antimicrobial resistance, is expanding its strategic collaboration with Sandoz, aimed at driving cutting-edge digital solutions in the global fight against antimicrobial resistance, and to that end has extended its collaboration agreement until January 31, 2025.

• OpGen Announces Interim Analysis Results from Clinical Trial for Unyvero Urinary Tract Infection Panel

  4/5/2022

  OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of

• OpGen Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

  3/29/2022

  OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today its fourth quarter 2021 and full-year 2021 financial and operating results and provided a business update.

• OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2021 on March 29th at 4:30 p.m. Eastern Time

  3/15/2022

  OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its fourth quarter and full year 2021 financial results after the close of the U.S. financial markets on Tuesday, March 29th, 2022.

• OpGen Announces Successful Completion of Unyvero A30 Development Milestone

  2/10/2022

  OpGen, Inc. announced today that its subsidiary Curetis has successfully met a key milestone in the development of the new Unyvero A30 RQ platform instruments.

• OpGen Announces Publication of Results from the Acuitas AMR Gene Panel Multicenter Clinical Trial in the Journal of Clinical Microbiology

  2/10/2022

  OpGen, Inc. announced the release of a new peer-reviewed journal publication that demonstrates that the Acuitas® AMR Gene Panel accurately detects and differentiates 28 genetic antimicrobial resistance markers performed on isolated colonies from 26 different pathogens.

• OpGen to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022

  1/18/2022

  OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced it is participating in Edison Group’s Open House Event, scheduled to take place virtually this month.

• OpGen Announces Preliminary Unaudited Revenue for Fiscal 2021 and Provides Business Update

  1/10/2022

  OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced that total preliminary unaudited revenue for OpGen in 2021 was approximately $4.3 million, compared to approximately $4.2 million in 2020.

• OpGen subsidiary Ares Genetics announces the strategic expansion of ARESdb proprietary contents

  12/14/2021

  Following successful completion of Phase 1, Ares Genetics has now entered into Phase 2 of its collaboration with a leading U.S. CRO and reference lab, gaining access to 1,000 proprietary clinical isolates from key pathogens ARESdb contents has grown by more than 40% in a year.

• OpGen Announces Results of Special Meeting of Stockholders - Dec 08, 2021

  12/8/2021

  OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced that stockholders have approved the two proposals voted on at the Company’s Special Meeting of Stockholders held on December 8, 2021.

• OpGen Reports Third Quarter 2021 Financial Results and Provides Business Update

  11/11/2021

  OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its financial and operating results for the three and nine months ended September 30, 2021, and provided a business update.

• OpGen Appoints Albert Weber as Chief Financial Officer

  11/4/2021

  OpGen, Inc today announced the appointment of Albert Weber as OpGen’s new Chief Financial Officer and Managing Director of OpGen’s subsidiary Curetis GmbH effective January 1, 2022.

• OpGen Announces Special Meeting of Stockholders to Vote on Proposed Increase to Number of Authorized Shares of Common Stock

  11/4/2021

  OpGen, Inc. announced it has scheduled a Special Meeting of stockholders for December 8, 2021 at 10:00 a.m., Eastern time, to approve its proposed increase of the number of authorized shares of common stock

• OpGen to Provide Business Update and Financial Results for the Third Quarter 2021 on November 11th at 4:30 p.m. Eastern Time

  10/28/2021

  OpGen, Inc. announced today that the Company will provide a business update and report its third quarter 2021 financial results after the close of the U.S. financial markets on Thursday, November 11, 2021.

• OpGen Subsidiary Ares Genetics Launches AREScloud

  10/21/2021

  OpGen, Inc today announced that its subsidiary Ares Genetics has commercially launched its AREScloud web application.

• OpGen Announces Closing of $15 Million Registered Direct Offering

  10/18/2021

  OpGen, Inc. today announced the closing of its previously announced registered direct offering with a single healthcare-focused institutional investor of 150,000 shares of convertible preferred stock